search

Active clinical trials for "Neoplasms"

Results 4201-4210 of 64586

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial...

Metastatic CancerEndometrium Cancer1 more

It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.

Recruiting36 enrollment criteria

Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

Advanced Soft-tissue Sarcoma

This is an Interventional Study in Advanced Soft Tissue Sarcomas (ASTS). It is a Phase 1b, open-label, dose-escalation clinical study evaluating the safety of camsirubicin with prophylactic pegfilgrastim in the treatment of advanced soft tissue sarcomas. The objective of the study is to evaluate the safety of camsirubicin with prophylactic pegfilgrastim in the treatment of ASTS and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of camsirubicin with prophylactic pegfilgrastim. The primary endpoint is the MTD (RP2D).The secondary endpoints are: safety profile of camsirubicin with prophylactic pegfilgrastim, PFS, TTP, ORR, DoR, OS and PK. As exploratory endpoint, Quality of life will be measured by using the Functional Assessment of Cancer Therapy: General (FACT-G).

Recruiting39 enrollment criteria

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Head and Neck Squamous Cell Carcinoma

The purpose of this study is to investigate whether the addition of metronomic capecitabine to the standard treatment can improve prognosis in locoregionally advanced head and neck squamous cell carcinoma.

Recruiting20 enrollment criteria

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-12 more

This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tagraxofusp and decitabine may help to control the disease in patients with chronic myelomonocytic leukemia.

Recruiting34 enrollment criteria

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Recruiting22 enrollment criteria

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma

This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.

Recruiting99 enrollment criteria

A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse...

Recruiting

This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study. Primary objective: The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and rituximab plus CHOP, as first-line treatment of diffuse large B-cell lymphoma. Secondary objective: The purpose is to compare the safety of H02 combined with CHOP regimen and rituximab injection (Rituximab®) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.

Recruiting29 enrollment criteria

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated...

Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer

The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.

Recruiting25 enrollment criteria

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With...

Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia Refractory2 more

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

Recruiting42 enrollment criteria

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable...

Locally Advanced Skin Squamous Cell CarcinomaResectable Skin Squamous Cell Carcinoma1 more

This phase I trial tests the safety and side effects radiotherapy in combination with atezolizumab in treating patients with cutaneous squamous cell cancer that has spread to nearby tissue or lymph nodes (locally advanced) and can be removed from surgery (resectable) or cannot be remove by surgery (unresectable). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiotherapy in combination with atezolizumab may help improve outcomes for remission (cancer that is under control) than taking either treatment separately.

Recruiting51 enrollment criteria
1...420421422...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs